Comprehensive insights into oral squamous cell carcinoma: Diagnosis, pathogenesis, and therapeutic advances
- PMID: 39111016
- DOI: 10.1016/j.prp.2024.155489
Comprehensive insights into oral squamous cell carcinoma: Diagnosis, pathogenesis, and therapeutic advances
Abstract
Oral squamous cell carcinoma (OSCC) is considered the most common type of head and neck squamous cell carcinoma (HNSCC) as it holds 90 % of HNSCC cases that arise from multiple locations in the oral cavity. The last three decades witnessed little progress in the diagnosis and treatment of OSCC the aggressive tumor. However, in-depth knowledge about OSCC's pathogenesis, staging & grading, hallmarks, and causative factors is a prime requirement in advanced diagnosis and treatment for OSCC patients. Therefore present review was intended to comprehend the OSCCs' prevalence, staging & grading, molecular pathogenesis including premalignant stages, various hallmarks, etiology, diagnostic methods, treatment (including FDA-approved drugs with the mechanism of action and side effects), and theranostic agents. The current review updates that for a better understanding of OSCC progress tumor-promoting inflammation, sustained proliferative signaling, and growth-suppressive signals/apoptosis capacity evasion are the three most important hallmarks to be considered. This review suggests that among all the etiology factors the consumption of tobacco is the major contributor to the high incidence rate of OSCC. In OSCC diagnosis biopsy is considered the gold standard, however, toluidine blue staining is the easiest and non-invasive method with high accuracy. Although there are various therapeutic agents available for cancer treatment, however, a few only are approved by the FDA specifically for OSCC treatment. The present review recommends that among all available OSCC treatments, the antibody-based CAR-NK is a promising therapeutic approach for future cancer treatment. Presently review also suggests that theranostics have boosted the advancement of cancer diagnosis and treatment, however, additional work is required to refine the role of theranostics in combination with different modalities in cancer treatment.
Keywords: Diagnosis and Treatment; Hallmarks; Molecular-pathogenesis; OSCC; Theranostics.
Copyright © 2024 Elsevier GmbH. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper
Similar articles
-
Hallmarks of Cancer-Related Newly Prognostic Factors of Oral Squamous Cell Carcinoma.Int J Mol Sci. 2018 Aug 16;19(8):2413. doi: 10.3390/ijms19082413. Int J Mol Sci. 2018. PMID: 30115834 Free PMC article. Review.
-
Tumour mismatch repair protein loss is associated with advanced stage in oral cavity squamous cell carcinoma.Pathology. 2019 Dec;51(7):688-695. doi: 10.1016/j.pathol.2019.08.005. Epub 2019 Oct 18. Pathology. 2019. PMID: 31630878
-
Emerging histological and serological biomarkers in oral squamous cell carcinoma: Applications in diagnosis, prognosis evaluation and personalized therapeutics (Review).Oncol Rep. 2023 Dec;50(6):213. doi: 10.3892/or.2023.8650. Epub 2023 Oct 20. Oncol Rep. 2023. PMID: 37859591 Free PMC article. Review.
-
Oral Squamous Cell Carcinoma Associated with Precursor Lesions.Cancer Prev Res (Phila). 2021 Sep;14(9):873-884. doi: 10.1158/1940-6207.CAPR-21-0047. Epub 2021 Jun 30. Cancer Prev Res (Phila). 2021. PMID: 34193432
-
Oral carcinogenesis and non-invasive biomarkers for the diagnosis of oral squamous cell carcinoma.J Pak Med Assoc. 2024 Feb;74(2):370-373. doi: 10.47391/JPMA.9020. J Pak Med Assoc. 2024. PMID: 38419239
Cited by
-
Targeting p53-p21 signaling to enhance mesenchymal stem cell regenerative potential.Regen Ther. 2025 Apr 7;29:352-363. doi: 10.1016/j.reth.2025.03.007. eCollection 2025 Jun. Regen Ther. 2025. PMID: 40248767 Free PMC article. Review.
-
Immunoexpression of CXCL12 and CXCR4 in oral tongue squamous cell carcinoma of young and older patients.Eur Arch Otorhinolaryngol. 2025 Apr;282(4):2105-2114. doi: 10.1007/s00405-024-09106-w. Epub 2024 Nov 29. Eur Arch Otorhinolaryngol. 2025. PMID: 39613853
-
Neoadjuvant immunochemotherapy versus neoadjuvant immunoradiotherapy in locally advanced oral squamous cell carcinoma.Front Immunol. 2025 May 8;16:1563737. doi: 10.3389/fimmu.2025.1563737. eCollection 2025. Front Immunol. 2025. PMID: 40406099 Free PMC article.
-
Salivary Extracellular Vesicles in Detection of Head and Neck Cancers: A Systematic Review.Int J Nanomedicine. 2025 May 26;20:6757-6775. doi: 10.2147/IJN.S520288. eCollection 2025. Int J Nanomedicine. 2025. PMID: 40452788 Free PMC article.
-
Thymidine Kinase 1 Expression Correlates with Tumor Aggressiveness and Metastatic Potential in OSCC.Diagnostics (Basel). 2025 Jun 19;15(12):1567. doi: 10.3390/diagnostics15121567. Diagnostics (Basel). 2025. PMID: 40564887 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical